METHODS FOR INHIBITING STENOSIS, OBSTRUCTION, OR CALCIFICATION OF A STENTED HEART VALVE OR BIOPROSTHESIS

• US 20140257473A1
• Filed: 04/28/2014
• Published: 09/11/2014
• Est. Priority Date: 10/22/2012
• Status: Abandoned Application

• Current Assignee: ConcieValve, LLC
• Original Assignee: ConcieValve, LLC
• Inventors: Rajamannan, Nalini Marie
• Application Number:
  US14/263,438
• Publication Number:
  US 20140257473A1
• Time in Patent Office: Days
• US Class Current: 623/2.14
• CPC Class Codes: A61F 2/2412 with soft flexible valve members, e.g. tissue valves shaped like natural valves check valves with flexible valve members in general F16K15/14
• CPC Class Codes: A61F 2/2418 Scaffolds therefor, e.g. support stents
• CPC Class Codes: A61F 2250/0067 Means for introducing or releasing pharmaceutical products into the body
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61L 2300/204 with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
• CPC Class Codes: A61L 2300/21 Acids
• CPC Class Codes: A61L 2300/258 Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/606 Coatings
• CPC Class Codes: A61L 2400/02 Treatment of implants to prevent calcification or mineralisation in vivo
• CPC Class Codes: A61L 2430/20 for reconstruction of the heart, e.g. heart valves
• CPC Class Codes: A61L 27/3625 Vascular tissue, e.g. heart valves
• CPC Class Codes: A61L 27/54 Biologically active materials, e.g. therapeutic substances A61L27/227 takes precedence
• CPC Class Codes: A61L 31/14 Materials characterised by their function or physical properties , e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence

Abstract

The present invention relates to methods for inhibiting stenosis, obstruction, or calcification of a valve following implantation of a valve prosthesis which may involve disposing a coating composition on an elastical stent or valve leaflet. The valve prosthesis is mounted on the elastical stent such that the elastical stent is in contact with the valve.

Claims

1. A method for inhibiting stenosis, obstruction, or calcification of a bioprosthetic valve following implantation of said bioprosthetic valve in a vessel having a wall, said method comprising:

providing a bioprosthetic valve for surgical replacement of a natural diseased valve, said bioprothestic value including an elastical stent;

providing a coating composition on said elastical stent, bioprosthetic valve or both, wherein the coating composition comprises one or more therapeutic agents;

implanting said bioprosthetic valve into said vessel by surgically removing a natural valve and replacing said natural valve with said bioprosthesis or placing said bioprosthesis over said natural valve having valve leaflets thereby compressing said natural valve leaflets against the vessel wall;

eluting said therapeutic agents from said elastical stent, bioprosthetic valve or both; and

causing the inhibition of stenosis, obstruction, or calcification of the bioprosthesis or the natural valve or both following implantation of the bioprosthetic valve.

2. The method according to claim 1, wherein the therapeutic agent is selected from paclitaxel, sirolimus, biolimus, everolimus or combinations of the foregoing.

3. The method according to claim 1, further comprising implanting said bioprosthetic valve by catheterization.

4. The method according to claim 1, wherein the bioprosthetic valve is an aortic bioprosthetic valve.

5. The method according to claim 1, wherein the bioprosthetic valve is a bioprosthetic mitral valve.

6. The method according to claim 1, wherein the bioprosthetic valve is a bioprosthetic pulmonic valve.

7. The method according to claim 1, wherein the bioprosthetic valve is bioprosthetic tricuspid valve.

8. The method according to claim 1, wherein the bioprosthetic valve comprises one or more cusps of biological origin.

9. The method according to claim 8, wherein the one or more cusps is porcine, bovine, or human.

10. The method according to claim 8, further comprising introducing a nucleic acid encoating a nitric oxide synthase into the one or more cusps.

11. The method according the claim 8, further comprising introducing a drug eluting treating encoating the one or more cusps on both sides with an anti-proliferative and anti-calcification treatment.

12. The method according to claim 1, wherein the elastical stent is substantially cylindrical.

24. The method of claim 1 wherein the elastical stent has a surface constructed and arranged to reduce neointimal proliferation.

26. The method of claim 1 wherein the bioprosthetic valve has a surface constructed and arranged to reduce neointimal proliferation and calcification.

33. The method of claim 1 further comprising providing a sewing ring operably coupled to said bioprosthetic valve, said sewing ring having a surface constructed and arranged to reduce neointimal proliferation.

13. The method according to clause 12, wherein the diameter of the elastical stent is about 15 mm to about 42 mm.

14. A valve prosthesis comprising:

an elastical stent;

a bioprosthetic valve having leaflets operably coupled to said elastical stent;

a therapeutic agent on the elastical stent, bioprosthetic valve on sides of the leaflets or both, said therapeutic agent structured to elute from said elastical stent, bioprosthetic valve leaflets or both;

wherein said bioprosthetic valve is structured to be implanted in vessel having a vessel wall to replace a natural diseased valve;

said bioprosthetic valve structured to inhibit stenosis, obstruction, or calcification of the bioprosthetic valve and natural valve following implantation of the bioprosthetic valve prosthesis.

15. The bioprosthetic valve of claim 14 wherein said bioprosthetic valve is coupled to a surgical sewing ring.

16. The bioprosthetic valve of claim 14, wherein the therapeutic agent is selected from paclitaxel, sirolimus, biolimus, everolimus, zotarolimus and combinations of the foregoing.

17. The bioprosthetic valve of claim 14, said valve sized and constructed to be implanted by catherization in a coronary valve of the patient.

18. The bioprosthetic valve of claim 14, wherein the valve is an aortic valve.

19. The bioprosthetic valve of claim 14, wherein the bioprosthetic valve comprises one or more cusps of biological origin.

20. The bioprosthetic valve of claim 19, wherein the one or more cusps are porcine, bovine, or human.

21. The bioprosthetic valve of claim 19 further comprising a nucleic acid encoating a nitric oxide synthases into one or more of the cusps.

22. The elastical stent of claim 14 sized, constructed and arranged in a substantially cylindrical configuration.

25. The valve prosthesis of claim 14 wherein the elastical stent has a surface constructed and arranged to reduce neointimal proliferation.

27. The valve prosthesis of claim 14, wherein the therapeutic agent is selected from paclitaxel, sirolimus, biolimus, everolimus, zotarolimus and combinations of the foregoing.

28. The bioprosthetic valve of claim 14, said valve is sized constructed and arranged to be implanted by catherization in a coronary valve of the patient.

29. The bioprosthetic valve of claim 14, wherein the valve is an aortic valve.

30. The bioprosthetic valve of claim 14, wherein the bioprosthetic valve comprises one or more cusps of biological origin.

31. The bioprosthetic valve of claim 30, wherein the one or more cusps are porcine, bovine, or human.

32. The bioprosthetic valve of claim 14 and further comprising a nucleic acid encoating a nitric oxide synthases into one or more of the cusps.

34. The valve prosthesis of claim 14 further comprising a sewing ring operably coupled to said bioprosthetic valve, said sewing ring having a surface constructed and arranged to reduce neointimal proliferation and pannus formation.

23. The valve prosthesis of clause 14 wherein a diameter of the elastical stent is about 15 mm to about 42 mm.